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   Benzodiazepines generally used as sedating, antianxiety, 
or anticonvulsant agents. In particular, diazepam 
(DZ), lorazepam (LZ), and clonazepam (CZ) are widely 
used for the management of acute epileptic seizures 
or status epilepticus[1]. Benzodiazepines (BDZ) are 
highly protein bound in plasma, and undergo extensive 
hepatic biotransformation. Due to a predominant hepatic 
metabolism, liver disease can significantly affect the 
metabolism of various benzodiazepines[2]. Antiepileptic 
drugs (AED) as therapeutic agents have been associated with 
severe hepatotoxicity. In a large series of drug-induced 
liver injury (DILI) reported to the Danish authorities in 
the 1970s and 1980s, a total of 8.3% out of all reports were 
AED[4]. We report a girl who developed hepatotoxicity due 
to clonazepam, which resolved promptly after cessation of 
therapy.
  A 7-year-old girl using oxcarpazepine followed with the 
diagnosis of cerebral palsy and epilepsy in our outpatient 
children for 5 years. She had a history of perinatal asphyxia. 
On physical examination, she had severe psychomotor 
retardation and could not walk and speak. Previously she 
used phenobarbital (4.2 mg/kg/d) for 4 years. She was using 
oxcarbazepine (22 mg/kg/d) for 2 years. Clonazepam (0.05 
mg/kg/d) was added to the therapy because of increment of 
her convulsion. Before initiation of clonazepam, hemogram, 
serum electrolytes, renal and liver function tests (aspartate 
aminotransferase (AST); 26 U/L, alanine aminotransferase 
(ALT); 20 U/L) were normal. On the 7 th day of clonazepam 
therapy she was readmitted to our outpatient clinic because 
her convulsion were continued. On that time hemogram, 
serum electrolytes, renal function tests were normal but 
AST and ALT were 195 U/L and 227 U/L, respectively. 
TORCH serology and the serologic profile of Hepatitis A, 
B and C were unremarkable. Abnormal liver function tests 
were thought due to clonazepam and it was immediately 
discontinued. 5 th day of cessation of clonazepam, serum 
AST and ALT levels were 33 and 31, respectively.
  DILI is a potential complication of many drugs. This 
is not surprising given the fact that the liver plays a 
central role in drug metabolism. Clobazam, clonazepam, 
diazepam, lorazepam and midazolam are commonly used 
BDZ in the treatment of epilepsy[3]. All BZDs share similar 
neuropharmacologic properties including anxiety reduction, 
sedation, sleep induction, anticonvulsant effects and muscle 
relaxation[5]. Diazepam and lorazepam are primarily used 
for management of seizure emergencies, whereas clobazam, 
clonazepam and clorazepate are commonly used in chronic 
epilepsy management[5]. The main limitations in the use of 
clonazepam have been side effects and the development 
of tolerance to its antiepileptic efficacy[6]. Many authors 
consider the side effects to be dose-dependent and found 
them to be diminished when the dose was reduced[6]. Barker 
et al[7], concluded that long term BZD users show recovery 
of function in visuospatial skills, attention/concentration, 
general intelligence, psychomotor speed and nonverbal 
memory assessments after withdrawal. A few case reports 
showing mild to moderate elevations in liver tests have been 
reported in association with oxcarbazepine[8].
   In conclusion, our case showed that hepatotoxicity might 
be seen during clonezapam therapy in children using 
oxcarpazepine.
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